Spyre Therapeutics, Inc. (SYRE)
$80.45-6.34%Close
SELLCRISIS · day 6
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $7.0B
- Beta
- 3.11
- P/E (TTM)
- -40.32
- Short % float
- 16.59%
- Days to cover
- 8.9
- SI change
- +5.9%
- 1W
- +0.42%
- 1M
- -11.40%
- vs SPY 1W
- +0.56%
- vs SPY 1M
- -13.90%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 0
- GROWTH
- 0
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-14.6%
REV YoY-
ROE-24.3%
EPS YoY-
ROA-15.3%
GROSS0
OP-222
NET-198
[VALUATION]
P/E TTM-40.32
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B6.05
P/FCF-
EV/EBITDA-35.93
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO18.53
ND/EBITDA-
BETA3.11
Company news
FAQ
- What is LOPJLB’s current signal on SYRE?
- LOPJLB’s latest quantitative signal on Spyre Therapeutics, Inc. (SYRE) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is SYRE in?
- Spyre Therapeutics, Inc. (SYRE) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Spyre Therapeutics, Inc. (SYRE) do?
- Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4Ã7 integrin. This particular therapy is under development for…